Nykode Therapeutics AS (OTCMKTS:VACBF) Short Interest Down 14.2% in February

Nykode Therapeutics AS (OTCMKTS:VACBF) was the recipient of a large decrease in short interest in February. As of February 27th, there was short interest totaling 1,059,580 shares, a decrease of 14.2% from the February 12th total of 1,235,218 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Nykode Therapeutics AS Price Performance

Shares of VACBF stock opened at $0.38 on Thursday. Nykode Therapeutics AS has a fifty-two week low of $0.16 and a fifty-two week high of $0.38. The firm’s 50 day moving average price is $0.31 and its two-hundred day moving average price is $0.24.

Nykode Therapeutics AS Company Profile

Nykode Therapeutics AS (OTCMKTS:VACBF) is a clinical-stage biotechnology company based in Oslo, Norway, focused on the development of precisely targeted immunotherapies. The company’s proprietary platform is designed to deliver antigenic payloads directly to antigen-presenting cells, with the goal of eliciting potent and durable immune responses against both cancerous and infectious disease targets. By combining modular antigen design with novel delivery modalities, Nykode aims to drive next-generation vaccine and immunotherapy solutions.

The company’s clinical pipeline includes several lead candidates in oncology and infectious diseases.